Skip to main content
    C

    Celldex Therapeutics Inc (CLDX)

    Official site

    HEALTHCARE • BIOTECHNOLOGY • NASDAQ

    $28.93
    +1.10 (+3.93%)

    Market Cap: $2.19B

    Last updated: Oct 16, 2026 at 1:54 PM ET

    Earnings

    Performance (10Y)

    Beat Rate
    59%(23/39)
    Avg Surprise
    -4.62%
    Streak
    1 Q

    Upcoming Estimates

    Period ending Sep 30, 2026
    EPS Consensus$-1.01
    Range$-1.07 - $-0.94
    10 analysts
    EPS Revisions
    6
    0
    7d
    5
    1
    30d
    EPS Estimate DriftChange to current
    90d ago$-1.08+6.5%
    60d ago$-1.08+6.1%
    30d ago$-1.01-0.6%
    7d ago$-1.010.0%
    Current$-1.01
    Revenue Consensus
    $883220
    Range$0 - $3M
    9 analysts
    Period ending Dec 31, 2026
    EPS Consensus$-0.92
    Range$-1.13 - $-0.51
    10 analysts
    Revenue Consensus
    $-716690
    Range$-2566600 - $4M
    11 analysts
    PeriodReportedEst.SurpriseB/MYoY
    Dec 26EST
    		-$-0.92---
    Sep 26EST
    		-$-1.01---
    Jun 26
    Reported Aug 6
    		$-0.94$-1.04+9.62%Beat-10.6%
    Mar 26
    Reported May 7
    		$-1.18$-1.13-4.42%Miss-45.7%
    Dec 25
    Reported Feb 25
    		$-1.22$-1.00-22.00%Miss-71.8%
    Sep 25
    Reported Nov 10
    		$-1.01$-0.89-13.48%Miss-57.8%
    Jun 25
    Reported Aug 7
    		$-0.85$-0.86+1.16%Beat-57.4%
    Mar 25
    Reported May 8
    		$-0.81$-0.74-9.46%Miss-44.6%
    Dec 24
    Reported Feb 27
    		$-0.71$-0.71+0.64%Beat+14.5%
    Sep 24
    Reported Nov 6
    		$-0.64$-0.67+4.48%Beat+21.0%
    Jun 24
    Reported Aug 8
    		$-0.54$-0.59+8.47%Beat+16.9%
    Mar 24
    Reported May 6
    		$-0.56$-0.67+16.42%Beat+9.7%
    Dec 23
    Reported Feb 26
    		$-0.83$-0.74-12.16%Miss-48.2%
    Sep 23
    Reported Nov 2
    		$-0.81$-0.66-22.73%Miss-42.1%
    Jun 23
    Reported Aug 8
    		$-0.65$-0.66+1.52%Beat-12.1%
    Mar 23
    Reported May 4
    		$-0.62$-0.60-3.33%Miss-24.0%
    Dec 22
    Reported Feb 28
    		$-0.56$-0.59+5.08%Beat-30.2%
    Sep 22
    Reported Nov 9
    		$-0.57$-0.57+0.00%Beat-54.1%
    Jun 22
    Reported Aug 8
    		$-0.58$-0.42-38.10%Miss-70.6%
    Mar 22
    Reported May 5
    		$-0.50$-0.43-16.28%Miss-19.0%
    Dec 21
    Reported Feb 28
    		$-0.43$-0.42-2.38%Miss+21.8%
    Sep 21
    Reported Nov 9
    		$-0.37$-0.35-5.71%Miss-2.8%
    Jun 21
    Reported Aug 5
    		$-0.34$-0.40+15.00%Beat+40.4%
    Mar 21
    Reported May 6
    		$-0.42$-0.37-13.51%Miss+42.5%
    Dec 20
    Reported Mar 29
    		$-0.55$-0.37-48.65%Miss+14.1%
    Sep 20
    Reported Nov 5
    		$-0.36$-0.38+5.26%Beat+52.0%
    Jun 20
    Reported Aug 6
    		$-0.57$-0.58+1.72%Beat+32.1%
    Mar 20
    Reported May 6
    		$-0.73$-0.72-1.39%Miss+47.9%
    Dec 19
    Reported Mar 26
    		$-0.64$-0.90+28.89%Beat+21.0%
    Sep 19
    Reported Nov 12
    		$-0.75$-0.84+10.71%Beat-25.0%
    Jun 19
    Reported Aug 7
    		$-0.84$-1.17+28.21%Beat+49.1%
    Mar 19
    Reported May 7
    		$-1.40$-1.14-22.81%Miss+88.9%
    Dec 18
    Reported Mar 7
    		$-0.81$-1.20+32.50%Beat+68.2%
    Sep 18
    Reported Nov 7
    		$-0.60N/A+76.47%Beat+80.0%
    Jun 18
    Reported Aug 8
    		$-1.65$-2.70+38.89%Beat+52.2%
    Mar 18
    Reported May 10
    		$-12.60$-3.03-315.84%Miss-200.0%
    Dec 17
    Reported Mar 7
    		$-2.55$-3.71+31.27%Beat+43.3%
    Sep 17
    Reported Nov 7
    		$-3.00$-4.01+25.19%Beat-
    Jun 17
    Reported Aug 8
    		$-3.45$-4.17+17.27%Beat-
    Mar 17
    Reported May 9
    		$-4.20$-4.31+2.55%Beat-
    Dec 16
    Reported Mar 14
    		$-4.50$-5.04+10.71%Beat-

    Key Metrics

    Valuation
    P/E Ratio-6.65EV/EBITDAN/A
    Price/FCF-9.30xFCF Yield-10.75%
    Profitability
    Profit Margin0.00%Operating Margin-366468.00%
    ROE-43.90%ROICN/A
    Financial Health
    Debt/Equity0.00xInterest CoverageN/A
    Current Ratio11.82xQuick Ratio11.82x
    Trading Statistics
    Beta0.90Avg Volume2.32M
    52-Week High$45.1452-Week Low$22.10

    Technical Indicators Dashboard

    Moving Averages

    SMA 10$29.93
    SMA 20$31.52
    SMA 50$36.87
    SMA 200$32.49
    EMA 10$29.80
    EMA 20$31.60
    EMA 50$34.43
    EMA 200$32.76

    MACD

    Line: -2.31Signal: -2.18Hist: -0.13

    ADX

    ADX: 26.2+DI: 12.9-DI: 29.6

    Aroon & PSAR

    Aroon Up28.0
    Aroon Down100.0
    PSAR$34.04

    Bollinger Bands

    Upper Band$36.89
    Lower Band$26.15
    %B Position3406%(Upper)
    Band Width0.26

    RSI (14-Day)

    Neutral
    32.7

    Momentum Oscillators

    Stoch %K11.4
    Stoch %D10.6
    Williams %R-75.5
    ROC (10d)-10.1%
    Momentum-3.25
    CCI (20d)-112.1
    MFI (14d)40.5

    Volatility Measures

    ATR (14d)$1.60(5.5%)
    StdDev (20d)2.68
    Hist Vol57.9%(High)

    Volume Flow

    VWAP$28.51
    OBV-21.9M
    AD Line3.3M
    CMF (20d)-0.074

    Volume Metrics

    Avg Vol (20d)2.4M
    Vol Ratio0.5x(Low)
    VWMA (20d)$31.89

    Pivot Points

    R3$29.53
    R2$29.13
    R1$28.48
    Pivot Point$28.08
    S1$27.43
    S2$27.03
    S3$26.38

    Advanced Oscillators

    TSI-40.43
    Ultimate Osc45.8
    KST-212.48

    Financial Data

    QuarterJun 2026Mar 2026Dec 2025Sep 2025Jun 2025Mar 2025Dec 2024Sep 2024Jun 2024Mar 2024Dec 2023Sep 2023
    Total Revenue$22,000$15,000$120,000$0$730,000$695,000$1.18M$3.19M$2.50M$156,000$4.13M$1.52M
    Cost of Revenue$0$0N/A$0$0$0$819,000$0$0$0$30.43M$0
    Gross Profit$22,000$15,000$120,000$0$730,000$695,000$1.18M$3.19M$2.50M$156,000$4.13M$1.52M
    Operating Expenses$80.64M$84.45M$87.27M$73.62M$64.59M$63.43M$57.20M$55.32M$48.81M$40.76M$51.76M$42.76M
    R&D$67.54M$73.00M$75.33M$62.93M$54.20M$52.61M$46.94M$45.26M$39.69M$31.66M$30.43M$34.53M
    SG&A$13.10M$11.45M$11.94M$10.69M$10.39M$10.82M$10.26M$10.05M$9.13M$9.10M$8.83M$8.22M
    Operating Income$-80,623,000$-84,435,000$-87,154,000$-73,617,000$-63,857,000$-62,739,000$-56,027,000$-52,126,000$-46,317,000$-40,608,000$-47,627,000$-41,239,000
    Interest Income$7.12M$5.75M$5.84M$6.57M$7.26M$8.94M$8.94M$10.01M$10.47M$7.80M$4.32M$2.98M
    Interest Expense$0$0$0$0$0$0$0$0$0$0$93.80M$0
    Income Before Tax$-73,503,000$-78,685,000$-81,317,000$-67,044,000$-56,600,000$-53,796,000$-47,092,000$-42,121,000$-35,842,000$-32,808,000$-141,429,000$0
    Income Tax Expense$0$0$0$0$0$0$0$0$0$0$0$0
    Net Income$-73,503,000$-78,685,000$-81,317,000$-67,044,000$-56,600,000$-53,796,000$-47,092,000$-42,121,000$-35,842,000$-32,808,000$-43,306,000$-38,260,000
    EBITDA$-81,419,000$-84,211,000$-87,220,000$-73,811,000$-64,672,000$-64,139,000$-58,571,000$-55,673,000$-50,260,000$-43,146,000$-49,047,000$-42,099,000
    EBIT$-80,623,000$-84,435,000$-87,154,000$-73,617,000$-63,857,000$-62,739,000$-56,027,000$-52,126,000$-46,317,000$-40,608,000$-47,627,000$-41,239,000
    * Some calculated fields are derived from available data when not provided by source

    Related GNG Research

    No research available

    Be the first to write about CLDX

    News

    November 9 earnings date set for Celldex Therapeutics stock

    Celldex Therapeutics (CLDX) has set November 9, 2026, as its next estimated earnings date, providing investors with an upcoming milestone for the clinical-stage biotechnology company. As of October 15, 2026...

    ad-hoc-news.de•10/15/26•Neutral

    Law firm investigates Celldex Therapeutics for possible breach of fiduciary duties.

    Purcell & Lefkowitz LLP is investigating Celldex Therapeutics to determine if the company's directors breached their fiduciary duties through recent corporate actions. This investigation...

    Pluang•10/12/26•Bearish

    Celldex Therapeutics Inc (TCE2.MU) Analyst insights, Price targets and Recommendations

    The article provides a snapshot of recent analyst ratings and recommendations for Celldex Therapeutics Inc (TCE2.MU), detailing upgrades, downgrades...

    Yahoo Finance UK•10/8/26•Neutral

    FMR LLC and Abigail P. Johnson Reveal 10.7% Stake in Celldex Therapeutics Inc.

    FMR LLC and Abigail P. Johnson have disclosed a 10.7% beneficial ownership stake in Celldex Therapeutics Inc. as of September 30...

    Kalkine Media•10/7/26•Neutral

    An investment firm reports a passive stake of 8.4 million shares in Celldex Therapeutics (CLDX).

    FMR LLC has filed an amended passive investment disclosure (SCHEDULE 13G/A) for Celldex Therapeutics (CLDX), reporting beneficial ownership of 8,411,905 shares...

    Stock Titan•10/7/26•Neutral

    CLDX Valuation and Fair Value

    P/E
    -6.7x
    P/FCF
    -9.3x
    PEG
    0.0x
    P/B
    3.2x
    See GNG's fair value

    CLDX Profitability: Margins, ROIC and FCF

    Operating margin
    -366468.0%
    Net margin
    0.0%
    ROE
    -43.9%
    FCF margin
    -154207.0%
    FCF yield
    -10.8%

    CLDX Competitors

    CompanyTicker
    NeoGenomics IncNEO
    Harmony Biosciences HoldingsHRMY
    Bausch Health Companies IncBHC
    Aurinia Pharmaceuticals IncAUPH
    Perrigo Company PLCPRGO
    Disc Medicine Inc.IRON
    Day One Biopharmaceuticals IncDAWN
    Progyny IncPGNY

    Sector: Healthcare

    CLDX Analyst Ratings

    Consensus
    Buy
    Analysts
    15
    Strong Buy
    2
    Buy
    12
    Hold
    1
    Sell
    0
    Strong Sell
    0

    CLDX Bull Case vs Bear Case

    Bull case

    • 93.3% of CLDX's analyst ratings are Buy or Strong Buy.

    Bear case

    • CLDX's quarterly revenue changed -97.0% year over year.

    CLDX Earnings: Beat Rate and Next Report

    Beat rate
    4 of 8 quarters (50.0%)
    Average surprise
    -4.2%
    EPS estimate (fiscal period ending Sep 30, 2026)
    $-1.01
    Estimate revisions (30 days, fiscal period ending Sep 30, 2026)
    5 up, 1 down

    Frequently Asked Questions About CLDX

    Does CLDX pay dividends?

    Celldex Therapeutics Inc (CLDX) does not currently pay a regular dividend.

    What is CLDX's market cap?

    Celldex Therapeutics Inc (CLDX) has a market capitalization of $2.19B with a current stock price of $28.93.

    Related stocks

    Sector: Healthcare

    All stocks starting with C

    Get full access to GNG Research

    Create a free account to access portfolio tracking, advanced tools, and more.

    Create Free AccountLog In